33774500 34359587 32050640 31310736 35625985 34207383 34820423 34896436 34948163 32480220 36532885 32969034 34175552 35007301 31708456 33362547 32596609 33920887 35671973 32385114 32144147 32849292 34262394 36534032 - Search Results

Year	Number of Results
2019	2
2020	9
2021	9
2022	6
2023	0

1

Abnormal alternative splicing promotes tumor resistance in targeted therapy and immunotherapy.

Deng K, Yao J, Huang J, Ding Y, Zuo J. Deng K, et al. Transl Oncol. 2021 Jun;14(6):101077. doi: 10.1016/j.tranon.2021.101077. Epub 2021 Mar 26. Transl Oncol. 2021. PMID: 33774500 Free PMC article. Review.

2

From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells.

Barazetti JF, Jucoski TS, Carvalho TM, Veiga RN, Kohler AF, Baig J, Al Bizri H, Gradia DF, Mader S, Carvalho de Oliveira J. Barazetti JF, et al. Cancers (Basel). 2021 Jul 22;13(15):3688. doi: 10.3390/cancers13153688. Cancers (Basel). 2021. PMID: 34359587 Free PMC article. Review.

3

Targeting Cancer Metabolism to Resensitize Chemotherapy: Potential Development of Cancer Chemosensitizers from Traditional Chinese Medicines.

Guo W, Tan HY, Chen F, Wang N, Feng Y. Guo W, et al. Cancers (Basel). 2020 Feb 10;12(2):404. doi: 10.3390/cancers12020404. Cancers (Basel). 2020. PMID: 32050640 Free PMC article. Review.

4

Breast cancer: Occluded role of mitochondria N-acetylserotonin/melatonin ratio in co-ordinating pathophysiology.

Anderson G. Anderson G. Biochem Pharmacol. 2019 Oct;168:259-268. doi: 10.1016/j.bcp.2019.07.014. Epub 2019 Jul 13. Biochem Pharmacol. 2019. PMID: 31310736 Review.

5

Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells.

Pal P, Millner A, Semina SE, Huggins RJ, Running L, Aga DS, Tonetti DA, Schiff R, Greene GL, Atilla-Gokcumen GE, Frasor J. Pal P, et al. Cancers (Basel). 2022 May 12;14(10):2380. doi: 10.3390/cancers14102380. Cancers (Basel). 2022. PMID: 35625985 Free PMC article.

6

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

You KS, Yi YW, Cho J, Park JS, Seong YS. You KS, et al. Pharmaceuticals (Basel). 2021 Jun 18;14(6):589. doi: 10.3390/ph14060589. Pharmaceuticals (Basel). 2021. PMID: 34207383 Free PMC article. Review.

7

Sphingosine Kinase 1 Signaling in Breast Cancer: A Potential Target to Tackle Breast Cancer Stem Cells.

Hii LW, Chung FF, Mai CW, Ng PY, Leong CO. Hii LW, et al. Front Mol Biosci. 2021 Nov 8;8:748470. doi: 10.3389/fmolb.2021.748470. eCollection 2021. Front Mol Biosci. 2021. PMID: 34820423 Free PMC article. Review.

8

p21 activated kinase-1 and tamoxifen - A deadly nexus impacting breast cancer outcomes.

Rajendran S, Swaroop SS, Roy J, Inemai E, Murugan S, Rayala SK, Venkatraman G. Rajendran S, et al. Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188668. doi: 10.1016/j.bbcan.2021.188668. Epub 2021 Dec 9. Biochim Biophys Acta Rev Cancer. 2022. PMID: 34896436 Review.

9

Plasma Sphingosine-1-Phosphate Levels Are Associated with Progression of Estrogen Receptor-Positive Breast Cancer.

Ikarashi M, Tsuchida J, Nagahashi M, Takeuchi S, Moro K, Toshikawa C, Abe S, Ichikawa H, Shimada Y, Sakata J, Koyama Y, Sato N, Hait NC, Ling Y, Okuda S, Takabe K, Wakai T. Ikarashi M, et al. Int J Mol Sci. 2021 Dec 13;22(24):13367. doi: 10.3390/ijms222413367. Int J Mol Sci. 2021. PMID: 34948163 Free PMC article.

10

Trametes robiniophila Murr in the treatment of breast cancer.

Li C, Wang X, Chen T, Wang W, Yang Q. Li C, et al. Biomed Pharmacother. 2020 Aug;128:110254. doi: 10.1016/j.biopha.2020.110254. Epub 2020 May 29. Biomed Pharmacother. 2020. PMID: 32480220 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results